Companies /Healthcare

Biogen Inc

NASDAQ: BIIB Drug Manufacturers - General
$212.50
▼ $8.33 (−3.77%) today
Markets closed · 1:11am ET
24/7 Rating BUY
12-Month Price Target
$252.01 +17.9% upside

Set by 24/7 Wall St.’s proprietary analysis of professional targets, profit trajectory, sector, risk, and retail attention. How we calculate our price targets →

Current close $213.71
Street consensus $236.87
Ours vs. the Street +6.4%
$212.96Conservative$213.71Current$252.01Our Target$287.42Optimistic
12-Month Projection Historical Optimistic Target Conservative
$150$200$250Sep 2025Sep 2027Today$287.42$252.01$212.96
$150$200$250Sep 2025Sep 2027Today$287.42$252.01$212.96

Analyst Sentiment

35ANALYSTS
Buy2366%
Hold1131%
Sell13%
The Bottom Line

Biogen appears attractively valued at current levels. With a 17.9% upside to our $252.01 target, the risk-reward profile looks favorable for investors with a 12-month time horizon. Wall Street agrees, with 66% of analysts rating it a Buy.

The 24/7 Factor

Base Growth
Conservative growth baseline (reduced to avoid double-counting P/E growth)
1.05×
Sector Momentum
Defensive growth with aging population tailwinds
1.10×
Analyst Consensus
Moderate analyst optimism
+3.8%
Earnings Growth
Significant earnings decline
−3.0%
Volatility Adjustment
Lower volatility stock
+1.7%
Price Position
Trading near 52-week high
+1.5%
Read our full methodology →

5-Year Projection

Long-Term Forecast Optimistic Target Conservative
$210$280$350$420’26’27’28’29’30’31$433.75$358.27$242.41
$210$280$350$420’26’27’28’29’30’31$433.75$358.27$242.41

Prediction History

BIIB Price Target History Our Target Stock Price
$210$240$270Jun 11Sep 4$252.56$220.83
$210$240$270Jun 11Sep 4$252.56$220.83
Date Price Target Stock Price Rating Upside
$252.56 $220.83 BUY +14.4%
$292.79 $218.50 BUY +34.0%
$292.45 $216.78 BUY +34.9%
$266.33 $209.83 BUY +26.9%
$268.88 $207.94 BUY +29.3%
$265.32 $202.95 BUY +30.7%
$266.57 $200.62 BUY +32.9%
$263.53 $208.92 BUY +26.1%

Frequently Asked Questions

What is the BIIB stock price prediction for 2030?

Looking ahead to 2030, our model projects BIIB could trade at an average price of $323.10, with a potential range between $242.32 and $403.87. This represents a potential 51.2% return from today’s price. Long-term forecasts depend heavily on company execution, competitive dynamics, and broader market conditions.

Is BIIB a buy, sell, or hold right now?

24/7 Wall St. currently rates BIIB as a BUY. Strong upside (+17.9%) Among Wall Street analysts, 23 rate it Buy, 11 rate it Hold, and 1 rate it Sell.

What is the BIIB stock price target in an optimistic scenario?

In our optimistic scenario for BIIB, the stock could reach $287.42 over the next 12 months, representing a 34.5% gain from today’s price. This scenario assumes favorable conditions materialize, including strong earnings growth, positive market sentiment, and successful execution of company initiatives.

What is the downside risk for BIIB stock?

Our conservative scenario for BIIB projects a price of $212.96 over the next 12 months (-0.3% from current levels), suggesting relatively limited downside if headwinds materialize. No forecast is a guarantee. Position sizing and time horizon still matter.

Projections are estimates based on current data, updated daily. Not investment advice. Learn how we calculate these projections →